Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PLUS THERAPEUTICS, INC. Director's Dealing 2022

Apr 27, 2022

34301_dirs_2022-04-27_07132cd2-1a4a-4605-9ce2-0d598eed89ed.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PLUS THERAPEUTICS, INC. (PSTV)
CIK: 0001095981
Period of Report: 2022-04-26

Reporting Person: Sims Andrew John Hugh MacIntyre (Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-04-26 Common Stock P 3000 $0.672 Acquired 12230 Direct